8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 21, 2008 (August 18, 2008)

GENENTECH, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

1-9813	94-2347624
(Commission File No.)	(IRS Employer Identification No.)

1 DNA Way
South San Francisco, California 94080-4990
(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 225-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

EXHIBIT 10.1

EXHIBIT 10.2

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(e)

On August 18, 2008, the Special Committee (the “Special Committee”) of the Board of Directors of Genentech, Inc. (the “Company”) adopted a broad-based retention program to address any employee concerns created by the proposal of Roche Holding Ltd. (“Roche”) to acquire the shares of the Company not owned by Roche. The Special Committee received input from the Company and an outside compensation advisor with respect to the program. The Company’s Board of Directors, including the Roche representatives, had previously granted the Special Committee authority to implement such a program.

The Special Committee adopted two retention plans and two severance plans that together cover substantially all employees of the Company, including the Company’s Chief Executive Officer, Chief Financial Officer and the other executive officers who were named in the Summary Compensation Table of the Company’s Proxy Statement for its 2008 Annual Meeting of Stockholders (together, the “named executive officers”).

Retention Plans

The Genentech, Inc. Employee Retention Plan (the “Employee Retention Plan”) and the Genentech, Inc. Executive Retention Plan (the “Executive Retention Plan”, and together with the Employee Retention Plan, the “Retention Plans”), provide for retention bonuses payable to substantially all employees of the Company, including the named executive officers. The participants in the Executive Retention Program are the Company’s CEO, members of the Company’s Executive Committee, the Company’s senior vice presidents and vice presidents, the Company’s executive vice president, research drug discovery, the Company’s controller and chief accounting officer, and the Company’s treasurer.

The Retention Plans are being implemented in lieu of the Company’s planned 2008 stock option grants. The aggregate size of the Retention Plans is approximately $371 million in cash (assuming all employees remain to receive their full payment). The cash amount is approximately equal to the value of the stock options which were expected to be granted in the Company’s 2008 option grant program, calculated using the methodology used in the Company’s financial statements to value options (Black-Scholes) and applying a discount rate. The discount rate reflects the earlier payment dates of the retention bonus, as described below, relative to the vesting schedule which would have applied to the planned option grants.

The estimated GAAP and non-GAAP EPS impact of the retention bonus plan will be approximately 22 cents per share spread over the years 2008-2010 (approximately eight cents in the remainder of 2008, approximately 12 cents in 2009, and approximately two cents in 2010, assuming that full payout occurs on June 30, 2009). Had the 2008 stock option grant program been implemented instead, the estimated GAAP EPS impact would have been approximately 23 cents per share, spread over the years 2008-2013. However, as the 2008 stock option grant program has been cancelled, no charges will be incurred with respect to the 2008 stock option grant program. The impact of the bonus retention plan may vary depending on

when and to what extent the bonuses are paid in accordance with the Retention Plans as described below.

The retention bonus under the Retention Plans is established based on employee’s job level, and will be paid as follows:

• If a merger of the Company with Roche or an affiliate of Roche has not occurred on or before June 30, 2009, then 100% of the retention bonus will be paid on June 30, 2009, subject to the employee remaining employed by the Company on that date.

• If a merger of the Company with Roche or an affiliate of Roche has occurred on or before June 30, 2009, then:

• If vesting is not accelerated with respect to 100% of the Company’s then outstanding unvested stock options in connection with the merger, 100% of the retention bonus will be paid on the completion of the merger, subject to the employee remaining employed by the Company on the date the merger is completed, or

• If vesting is accelerated with respect to 100% of the Company’s then outstanding unvested stock options in connection with the merger, then 50% of the retention bonus will be paid on the completion of the merger, and the remaining 50% will be paid on the first anniversary of the completion of the merger, subject to the employee remaining employed by the Company on those dates.

In addition, in the event of a merger of the Company with Roche or an affiliate of Roche, any employee who is terminated without “cause” or resigns with “good reason” (within three months of the initial existence of the condition or event that constitutes “good reason”) will be entitled to receive any remaining unpaid retention bonus upon such termination. However, under the Executive Retention Plan, if such payment would be subject to Section 409A of the Internal Revenue Code, such payment will be delayed until the first payroll date that occurs following six months and one day following termination.

The amounts payable to the named executive officers are set forth below:

Named Executive Officer	Title	Total Retention Bonus
Arthur D. Levinson	Chief Executive Officer	$8,737,300
David A. Ebersman	Executive Vice President and Chief Financial Officer	$2,730,500
Susan D. Desmond-Hellmann	President, Product Development	$4,587,200
Richard H. Scheller	Executive Vice President, Research	$2,730,500
Stephen G. Juelsgaard	Executive Vice President, Chief Compliance Officer and Secretary	$2,730,500

Severance Plans

The Genentech, Inc. Employee Severance Plan (the “Employee Severance Plan”) and the Genentech, Inc. Executive Severance Plan (the “Executive Severance Plan”, and together with the Employee Severance Plan, the “Severance Plans”) provide that substantially all employees of the Company, including the named executive officers, will be entitled to receive specified payments and benefits if they are terminated “without cause” or resign for “good reason"(within three months of the initial existence of the condition or event that constitutes “good reason”) within 18 months following a merger with Roche or an affiliate of Roche. The participants in the Executive Severance Plan are the same as the participants in the Executive Retention Plan.

Participants in the Employee Severance Plan will be entitled to the following:

• A severance payment based on a designated number of weeks, multiplied by (A) the employee’s weekly base salary, plus (B) an amount equal to the average annual bonus paid to the employee over the past three years, expressed as a percentage of average annual salary, multiplied by the employee’s weekly base salary. The number of weeks will range from 18 weeks to 52 weeks, depending on the employee’s job level and tenure with the Company.

• Accelerated vesting of all stock options granted by the Company and outstanding as of the severance date.

• Continued medical group health and dental plan coverage for a period of time equal to the designated number of weeks used to determine the employee’s severance pay.

• Reimbursement for reasonable outplacement services for 60-180 days (depending on the employee’s job level) following the employee’s severance date.

• Reimbursement of legal fees and expenses incurred by the employee in successfully enforcing rights under the Plan.

Participants in the Executive Severance Plan will be entitled to the following:

• A severance payment based on the executive’s base salary and the average of the prior three years bonus.

• For the Chief Executive Officer, the severance payment will be three times base salary and the average of the prior three years bonus.

• For members of the Executive Committee (including the Executive Vice President and Chief Financial Officer and all of the named executive officers) the severance payment will two times base salary and the average of the prior three years bonus.

• For other executives, the severance payment will be based on a designated number of weeks, multiplied by (A) the executive’s weekly base salary, plus (B) an amount equal to the average annual bonus paid to the executive over the past three years, expressed as a percentage of average annual salary, multiplied by the executive’s weekly base salary. The number of weeks will

range from 52 weeks to 104 weeks, depending on the executive’s job level and tenure with the Company.

• Accelerated vesting of all stock options granted by the Company and outstanding as of the severance date.

• Continued medical group health and dental plan coverage.

• For the Chief Executive Officer, coverage will be for three years.

• For members of the Executive Committee, coverage will be for two years.

• For other executives, coverage will be equal to the number of weeks used to determine the executive’s severance pay.

• Reimbursement for reasonable outplacement services not to exceed 180 days following the executive’s severance date.

• Reimbursement of legal fees and expenses incurred by the executive in successfully enforcing rights under the Plan.

Payment of the severance benefits under both Severance Plans is conditioned upon the employee’s execution of a release of claims in favor of the Company. Benefits which are subject to Section 409A of the Internal Revenue Code will be delayed until the first payroll date that occurs following six months and one day following termination of employment.

2008 Annual Bonus

In addition, the Severance Plans provide that if a merger with Roche occurs, participants will be paid their earned and accrued bonus under the 2008 Bonus Plan on the normal payment date if the employee remains employed with the Company through such date or the employee was terminated without cause or resigns for good reason following the merger with Roche. If a merger with Roche occurs prior to the end of the Company’s 2008 fiscal year, special rules will apply to determine the amount of the 2008 Bonus Plan pool, where the applicable corporate performance goals that would have been measured at the end of the year will be deemed achieved (the “annual corporate performance goals”) and added to the actual year-to-date achievement of any other applicable performance goals other than the annual corporate performance goals.

Definitions of Cause and Good Reason

As used in the Employee Retention Plan and the Employee Severance Plan, “cause” means:

• Willful and continued material failure to perform the reasonable duties and responsibilities of such person’s position after the Company has provided such person with a written demand for performance that describes the basis for the Company’s belief that such person has not substantially performed his or her duties and such person has not corrected the failure within thirty (30) days of the written demand;

• Any act of personal dishonesty that is intended to result in substantial personal enrichment;

• Conviction of, or plea of nolo contendere to, a felony; or

• Any material violation of the Company’s policies or guidelines.

As used in the Employee Retention Plan and the Employee Severance Plan, “good reason” means the occurrence of one or more of the following without the person’s consent:

• A fifteen percent (15%) or more reduction in total annual cash compensation opportunity (base pay and target bonus opportunity) as compared to total annual cash compensation opportunity immediately prior to the Corporate Transaction; or

• Change in such person’s principal work location resulting in a new commute that is more than 50 miles greater than such person’s commute prior to the change.

As used in the Executive Retention Plan and the Executive Severance Plan, “cause” means:

• Willful and continued material failure to perform reasonable job duties and responsibilities;

• Any act of personal dishonesty that is intended to result in substantial personal enrichment;

• Conviction of, or plea of nolo contendere to, a felony that the Board of Directors of the Company reasonably believes has had or will have a detrimental effect on the Company’s reputation or business;

• Breach of any fiduciary duty owed to the Company that has a detrimental effect on the Company’s reputation or business; or

• Such person is found liable in any Securities and Exchange Commission or other civil or criminal securities law action, or enters into any cease and desist order with respect to such action.

As used in the Executive Retention Plan and the Executive Severance Plan, “good reason” means the occurrence of one ore more of the following, without the person’s consent:

• A fifteen percent (15%) or more reduction in total annual cash compensation opportunity (base pay and target bonus opportunity) as compared to total annual cash compensation opportunity immediately prior to the Corporation Transaction;

• Change in principal work location resulting in a new commute that is more than 50 miles greater than such person’s commute immediately prior to the change; or

• A material reduction in authority, duties and/or responsibilities as compared to such person’s authority, duties and/or responsibilities immediately prior to the completion of the merger with Roche or an affiliate of Roche (for example, but not by way of limitation, this determination will include an analysis of whether such person maintains at least the same level, scope and type of duties and responsibilities with respect to the management, strategy operations and business of the combined entity resulting from such transaction, taking the Company, Roche and their respective parent corporations, subsidiaries and other affiliates, together as a whole).

Item 8.01 Other Events.

See Item 5.02 above.

Item 9.01 Financial Statements and Exhibits

     (d) Exhibits.

10.1	Genentech, Inc. Executive Retention Plan
10.2	Genentech, Inc. Executive Severance Plan

Signatures

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Genentech, Inc.
Dated: August 21, 2008	By:	/s/ Stephen G. Juelsgaard
		Stephen G. Juelsgaard
		Executive Vice President, Secretary and Chief Compliance Officer

EXHIBIT INDEX

Exhibit	Description
10.1	Genentech, Inc. Executive Retention Plan
10.2	Genentech, Inc. Executive Severance Plan

EX-10.1

Exhibit 10.1

GENENTECH, INC.

EXECUTIVE RETENTION PLAN

     Genentech, Inc. hereby adopts this Executive Retention Plan (the “Plan”) effective as of August 18, 2008.

1. Purpose.

     (a) The Special Committee (as defined below), is evaluating a proposal by Roche Holding Ltd. or an Affiliate of Roche Holding Ltd. (collectively “Roche”) to acquire the shares of Company (as defined below) common stock it does not currently own for US$89 per share in cash. The Board recognizes that the consideration of such a proposal can be a distraction to its executives and can cause its executives to consider alternative employment opportunities. The Plan is intended to (i) ensure that the Company will have the continued dedication and objectivity of its executives notwithstanding the possibility or occurrence of a Change of Control (as defined below), and (ii) provide the Company’s executives with enhanced financial security and incentive and encouragement to remain with the Company notwithstanding the possibility or occurrence of a Change of Control.

     (b) The benefits provided under the Plan shall be in lieu of the stock option grants the Company otherwise would expect to make to its executives in September 2008. Instead, each Covered Executive (as defined below) will be eligible to receive a retention bonus under the Plan with a value equal to approximately the discounted Black-Scholes value (as determined by the Company) of the stock option grant the Covered Executive otherwise would have received in September 2008.

2. Definitions.

     (a) “Administrator” means the Special Committee, or in the event the Special Committee is dissolved by the Board, then another duly constituted committee of members of the Board, or officers of the Company as delegated by the Board.

     (b) “Affiliate” with respect to any entity means any corporation or any other entity (including, but not limited to, partnerships and joint ventures) controlling, controlled by, or under common control with the entity, whether now or hereafter existing, provided that prior to the earlier of a Change of Control or June 30, 2009, for the purposes of the Plan, the Company shall not constitute an Affiliate of Roche and Roche shall not constitute an Affiliate of the Company.

     (c) “Board” means the Company’s Board of Directors or the Special Committee.

     (d) “Cause” means:

          (i) The Covered Executive’s willful and continued material failure to perform the reasonable duties and responsibilities of his or her position after the Company has provided the Covered Executive with a written demand for performance that describes the basis for the

1

Company’s belief that the Covered Executive has not substantially performed his or her duties and the Covered Executive has not corrected the failure within thirty (30) days of the written demand;

          (ii) Any act of personal dishonesty taken by the Covered Executive in connection with his or her responsibilities as an employee of the Company and intended to result in his or her substantial personal enrichment;

          (iii) The Covered Executive’s conviction of, or plea of nolo contendere to, a felony that the Board reasonably believes has had or will have a material detrimental effect on the Company’s reputation or business;

          (iv) The Covered Executive’s breach of any fiduciary duty owed to the Company by the Covered Executive that has a material detrimental effect on the Company’s reputation or business; or

          (v) The Covered Executive being found liable in any Securities and Exchange Commission or other civil or criminal securities law action or entering any cease and desist order with respect to such action (regardless of whether or not the Covered Executive admits or denies liability).

     (e) “Change of Control” means a merger of the Company with Roche.

     (f) “Closing” will have the same definition as such term is defined in the definitive agreement governing the Change of Control.

     (g) “Company” means Genentech, Inc. and its Affiliates, and any successor thereto (as determined in accordance with Section 9 below).

     (h) “Company Options” means the then unvested portion of all of the Covered Executive’s outstanding options to purchase Company common stock granted or assumed under the Company’s equity plans or assumed plans as of the date of Covered Executive’s Covered Termination, including, without limitation, outstanding Company Options, outstanding awards to acquire Roche equity securities following an assumption or substitution of the Company Options by Roche, or any other rights substituted by Roche for Company Options, in connection with a Change of Control.

     (i) “Covered Executive” means each individual who is eligible to participate in the Plan in accordance with Section 4(a) below.

     (j) “Good Reason” means the occurrence of one or more of the following without the Covered Executive’s written consent:

          (i) A fifteen percent (15%) or more reduction in the Covered Executive’s total annual cash compensation opportunity (base salary and target bonus opportunity collectively) as compared to the Covered Executive’s total annual cash compensation opportunity immediately prior to the Closing;

2

          (ii) A change in the Covered Executive’s principal work location resulting in a new one-way commute that is more than fifty (50) miles greater than the Covered Executive’s one-way commute prior to the change in the Covered Executive’s principal work location, regardless of whether the Covered Executive receives an offer of relocation benefits; or

          (iii) A material reduction in the Covered Executive’s authority, duties and/or responsibilities as compared to the Covered Executive’s authority, duties and/or responsibilities in effect immediately prior to the Closing (for example, but not by way of limitation, this determination will include an analysis of whether the Covered Executive maintains at least the same level, scope and type of duties and responsibilities with respect to the management, strategy, operations and business of the combined entity resulting from such transaction, taking the Company, Roche and their respective parent corporations, subsidiaries and other affiliates, together as a whole).

     (k) “Participation Agreement” means the individual agreement (a form of which is shown in Appendix C) that identifies the potential Retention Bonus for certain Covered Executives.

     (l) “Payment Date” means:

          (i) June 30, 2009, if a Change of Control has not occurred on or prior to such date; or

          (ii) Each date on which a payment of all or a portion of a Covered Executive’s Retention Bonus is scheduled to be made in accordance with Sections 6(b) or 6(c) below, as applicable, if a Change of Control occurs on or prior to June 30, 2009.

     (m) “Plan” means this Executive Retention Plan.

     (n) “Section 409A” means Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and any guidance promulgated thereunder.

     (o) “Special Committee” means the Special Committee of the Board, duly constituted by resolution of the Board adopted by unanimous written consent on July 24, 2008.

3. Administration.

     With respect to all Covered Executives, the Plan will be interpreted and administered by the Administrator. The Administrator will have the power and discretion to construe the terms of the Plan and perform such acts as it deems necessary or appropriate to effect the purpose of the Plan. Notwithstanding the foregoing, if the Board, as the case may be, has delegated authority to one or more officers of the Company in accordance with Section 2(a) above, the delegate may not interpret or construe the terms of the Plan in a manner that would otherwise materially increase the cost or materially change the type or scope of benefits, whether individually or in the aggregate, to be provided under the Plan.

     The Administrator, or such officer or officers of the Company designated by the Special Committee, each of whom shall be deemed to be an “Administrator” solely for the purposes of this paragraph, shall provide each Covered Executive who is identified on Exhibit B with a Participation

3

Agreement on which the Administrator shall designate the amount of such Covered Executive’s Retention Bonus as determined in accordance with Section 5.

     The Administrator will not be liable for any action or determination made by the Administrator with respect to the Plan or any distribution paid under the Plan. All expenses and liabilities that the Administrator incurs in connection with the administration of this Plan will be borne by the Company. The Administrator will not be personally liable for any action, determination or interpretation made in good faith with respect to this Plan or any distribution paid hereunder, and the Administrator will be fully indemnified and held harmless by the Company in respect of any such action, determination or interpretation.

4. Eligibility.

     (a) Each of the Company’s Chief Executive Officer, the Company’s President, Product Development, each member of the Company’s Executive Committee, the Company’s Executive Vice President, Research Drug Discovery, the Company’s Controller and Chief Accounting Officer, the Company’s Treasurer, and each Senior Vice President or Vice President of the Company shall be eligible to participate in this Plan, provided that such individual is employed by the Company on August 18, 2008, and is not excluded from the Plan by Section 4(b) below. Notwithstanding anything to the contrary herein, a Covered Executive described in the preceding sentence who is on short-term disability leave, as determined in accordance with the Company’s leave policies, on the Payment Date will continue to be eligible to receive a Retention Bonus.

     (b) An employee of the Company will not be eligible to participate in the Plan if:

          (i) The Company hires or rehires the employee after August 18, 2008.

          (ii) On June 30, 2009, the employee is on a Company Performance Improvement Plan and a Change of Control has not occurred on or prior to such date.

          (iii) On June 30, 2009, the employee is on long-term disability leave, as determined in accordance with the Company’s leave policies, and a Change of Control has not occurred on or prior to such date.

5. Amount of Retention Bonus.

     Each Covered Executive will be eligible to earn a retention bonus under the Plan (the “Retention Bonus”). The Retention Bonus will be a fixed dollar amount determined as a function of the Covered Executive’s job category and job level as specified in Appendix A or Appendix B or otherwise set forth in written resolutions of the Special Committee.

6. Payment of Retention Bonus.

     If the conditions for payment of any Retention Bonus set forth in this Plan are satisfied, the payment of the Retention Bonus will occur as follows:

     (a) If a Change of Control occurs on or before June 30, 2009, and vesting accelerates as to one hundred percent (100%) of the Company Options in connection with the Change of Control,

4

fifty percent (50%) of the Retention Bonus will be paid in a lump-sum payment on the date of the Closing and the remaining fifty percent (50%) of the Retention Bonus will be paid in a lump-sum payment on the first anniversary of the Closing.

     (b) If a Change of Control occurs on or before June 30, 2009, and vesting accelerates as to less than one hundred percent (100%) of the Company Options in connection with the Change of Control, one hundred percent (100%) of the Retention Bonus will be paid in a lump-sum payment on the date of the Closing.

     (c) If the Company does not consummate a Change of Control on or before June 30, 2009, one hundred percent (100%) of the Retention Bonus will be paid in a lump-sum payment on June 30, 2009.

7. Termination and Forfeiture of bonus Amounts.

     (a) Except as otherwise provided in Section 7(c) or Section 7(d) below, a Covered Executive must remain employed with the Company through the applicable Payment Date in order to receive his or her Retention Bonus (or the portion thereof) that is scheduled to be paid on such date.

     (b) If a Change of Control does not occur on or prior to June 30, 2009, and prior to such date, a Covered Executive: (i) voluntarily terminates his or her employment, or (ii) is terminated for any reason (including, but not limited to, a termination due to poor performance, a termination for Cause, or the elimination of the Covered Executive’s position), he or she will not receive a Retention Bonus. Any Retention Bonus not paid to a Covered Executive will revert to the Company and will not be reallocated to any other Covered Executive.

     (c) If, on or after a Change of Control, the Covered Executive is terminated by the Company other than for Cause or the Covered Executive terminates his or her employment for Good Reason within three (3) months of the initial existence of the condition or event that constitutes Good Reason, then any unpaid Retention Bonus (or portion thereof) will be paid as soon as practicable following the date of such termination (but in no event later than thirty (30) days following the date of such termination).

     (d) If Retention Bonuses are payable in accordance with Section 6(a) above and a Covered Executive dies after the Closing but prior to the final Payment Date, the portion of his or her Retention Bonus scheduled to be paid in a lump-sum payment on the first anniversary of the Closing shall be paid to his or her designated beneficiary, if the Administrator permits the designation of a beneficiary, or, if no beneficiary has been designated (or the Administrator determines that it will not permit the designation of a beneficiary), to his or her estate on the first anniversary of the Closing.

8. Amendment or Termination of the Plan.

     Although the Company currently expects to continue the Plan, the Administrator reserves the right to amend or terminate the Plan at any time. After a Change of Control, the Company may not, without the Covered Executive’s written consent, amend or terminate the Plan in any way that (a) prevents the Covered Executive from becoming eligible for his or her Retention Bonus under the

5

Plan, or (b) reduces the amount of Retention Bonuses payable, or potentially payable, to a Covered Executive under the Plan. Any Plan amendment or termination will be made in writing and approved by the Administrator.

9. Assumption by Successor.

     Any successor to the Company of all or substantially all of the Company’s business and/or assets (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise), will assume the obligations under this Plan and agree expressly to perform the obligations under this Plan in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Plan, the term “Company” will include any successor to the Company’s business and/or assets which become bound by the terms of this Plan by operation of law, or otherwise.

10. Rights Under the Plan.

     This Section 10 will survive the consummation of the Change of Control and the Closing. This Plan is intended to benefit, and may be enforced by, the Covered Executive and his or her respective heirs, representatives, successors and assigns, and will be binding on all successors and assigns of the Company and Roche.

11. No Guarantee of Future Service.

     Participation in the Plan will not provide any guarantee or promise of continued service of the Covered Executive with the Company, and the Company retains the right to terminate the employment of any Covered Executive at any time, with or without Cause, for any reason or no reason. However, as described in the Plan, a Covered Executive who terminates employment on or after a Change of Control may be entitled to benefits under the Plan depending upon the circumstances of the Covered Executive’s termination of employment.

12. Taxes.

     (a) The Company will withhold from any distributions under the Plan any amount required to satisfy any applicable income, employment and other tax withholding obligations.

     (b) Notwithstanding anything to the contrary in this Plan, if the Company determines that the Covered Executive is a “specified employee” within the meaning of Section 409A at the time of the Covered Executive’s termination of employment (other than due to death), then to the extent delayed commencement of any portion of the benefits to which the Covered Executive is entitled pursuant to this Plan, when considered together with any other payments or benefits that are considered deferred compensation under Section 409A (together, the “Deferred Compensation Separation Benefits”), is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such Deferred Compensation Separation Benefits will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of the Covered Executive’s termination of employment. All subsequent Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. An employee generally will be a specified employee only if (among other things) he or she owns at least one percent (1%) of the Company’s stock or is

6

considered an officer of the Company. The Company will inform the Covered Executive if it determines that he or she is a specified employee at the time of his or her termination. Notwithstanding anything herein to the contrary, if the Covered Executive dies following his or her termination but prior to the six (6) month anniversary of his or her termination, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of the Covered Executive’s death.

     (c) The foregoing provisions of this Plan are intended to comply with the requirements of Section 409A so that none of the benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company reserves the right to amend the Plan and to take such reasonable actions which are necessary, appropriate, or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to a Covered Executive under Section 409A, provided that such amendment or action may not materially reduce the benefits provided or to be provided to the Covered Executive under the Plan. In no event will the Company reimburse the Covered Executive for any taxes that may be imposed on him or her as a result of Section 409A.

13. Funding.

     No provision of the Plan will require the Company, for the purpose of satisfying any obligations under the Plan, to purchase assets or place any assets in a trust or other entity to which contributions are made or otherwise to segregate any assets, nor will the Company maintain separate bank accounts, books, records or other evidence of the existence of a segregated or separately maintained or administered fund for such purposes. Nothing contained in this Plan and no action taken pursuant to the provisions of the Agreement will create or be construed to create a trust of any kind. No property that may be acquired or invested by the Company in connection with the Plan will be deemed a security for the obligations to the Covered Executives hereunder, but will be, and continue for all purposes to be, part of the general funds of the Company. Covered Executives will have no rights under the Plan other than as unsecured general creditors of the Company.

14. Bonus Plan.

     This Plan is intended to be a “bonus program” as defined under U.S. Department of Labor regulation 2510.3-2(c) and will be construed and administered in accordance with such intention.

15. Nonassignability.

     To the maximum extent permitted by law, a Covered Executive’s right or benefits under this Plan will not be subject to anticipation, alienation, sale, assignment, pledge, encumbrance or charge, and any attempt to anticipate, alienate, sell, assign, pledge, encumber or charge the same will be void. No right or benefit hereunder will in any manner be liable for or subject to the debts, contracts, liabilities or torts of the person entitled to such benefit.

16. Choice of Law.

     All questions concerning the construction, validation and interpretation of the Plan will be governed by the laws of the State of California without regard to its conflict of laws provisions.

7

17. Headings.

     The headings in the Plan are inserted for convenience only and will not be deemed to constitute a part hereof nor to affect the meaning thereof.

18. Entire Agreement.

     This Plan and the corresponding Participation Agreement for each Covered Executive (if applicable), together with any benefits payable to such Covered Executive under the Genentech, Inc. Executive Severance Plan (the “Severance Plan”) constitute the entire understanding and agreement with respect to the subject matter contained herein, and there are no agreements, understandings, restrictions, representations or warranties among any Covered Executive and the Company other than those as set forth or provided for herein and in the Severance Plan.

[Remainder of Page Intentionally Left Blank]

8

     An authorized officer of the Company hereby adopts the Executive Retention Plan effective as of August 18, 2008.

GENENTECH, INC.
By:	/s/ Stephen G. Juelsgaard
	Stephen G. Juelsgaard
	Executive Vice President, Secretary and Chief Compliance Officer

9

Appendix A

The Covered Executive’s total Retention Bonus will be determined based on the Covered Executive’s job category and job level as follows:

Job Category	Job Level		Retention Bonus Amount
Chief Executive Officer		O4	$	8,737,300
President, Product Development	PRES		$	4,587,200
Executive Committee Members		O3	$2,730,500 per Executive Committee Member

For purposes of example only, if the Covered Executive is an Executive Committee Member, his or her individual Retention Bonus will be $2,730,500.

1

Appendix B

For the following individuals, the Retention Bonus amounts will be as provided in individual Participation Agreements:

Executive Vice President, Research Drug Discovery
Treasurer
Controller and Chief Accounting Officer
Senior Vice President
Vice President

1

Appendix C

Executive Retention Plan

Participation Agreement

     Unless otherwise defined herein, the terms defined in the Executive Retention Plan (the “Plan”) will have the same meanings in this Participation Agreement.

PARTICIPANT NAME: [NAME]

EMPLOYEE ID NUMBER: [ID NUMBER]

     Genentech, Inc. (the “Company”) is pleased to inform you, the participant named above, that you are a Covered Executive under the Plan. Pursuant to the terms of the Plan, you are eligible to receive a Retention Bonus as follows:

     Retention Bonus Amount: $[AMOUNT]

     Assuming you meet the requirements of the Plan, you will receive your Retention Bonus in accordance with the payment schedule set forth in Section 6 of the Plan (and subject to the other restrictions and limitations set forth in the Plan).

GENENTECH, INC.

By:

Print Name:

Title: 

2

EX-10.2

Exhibit 10.2

Genentech, Inc.

Executive Severance Plan and

Summary Plan Description

Who is Eligible:

You are considered eligible for Severance Benefits (as defined below) and will be deemed an “eligible executive” under the Executive Severance Plan (the “Plan”) if you meet all of the following eligibility criteria:

• You are a regular employee (full time or part time) of Genentech, Inc. or one of its affiliates (collectively, the “Company”), but Roche (as defined below) will not be considered an affiliate of Genentech, Inc. prior to the closing of the Corporate Transaction;

• Your employment with the Company terminates as a result of a Covered Termination (as defined below);

• Immediately prior to the closing of a Corporate Transaction (as defined below), you are one of the following: the Company’s Chief Executive Officer (CEO), the Company’s President, Product Development (the “President”), a member of the Company’s Executive Committee, the Company’s Executive Vice President, Research Drug Discovery (the “EVPRDD”), a Senior Vice President of the Company (“SVP”), the Company’s Controller and Chief Accounting Officer (the “Controller”), the Company’s Treasurer (the “Treasurer”), or a Vice President of the Company; and

• You execute the Company’s form of Agreement and Release (the “Release”) and it becomes binding.

However, you will not be an eligible executive for the purposes of the Plan if you meet any of the criteria set forth in the section entitled “Who is not Eligible”.

Who is not Eligible:

Even if you otherwise meet the eligibility criteria identified above, you are ineligible for Severance Benefits and shall not be deemed an eligible executive under the Plan if you meet any of the following criteria:

• You are classified by the Company as an independent contractor or any other status in which you are not treated as a common law employee of the Company for purposes of withholding taxes, regardless of your actual status;

• You voluntarily terminate your employment with the Company for any reason prior to the closing of the Corporate Transaction or without Good Reason (as defined below) after the closing of the Corporate Transaction;

• The Company terminates your employment for Cause (as defined below) or your employment with the Company terminates due to your death or disability;

Page 1

• You are eligible for benefits under the Employee Severance Plan; or

• You fail to comply with the terms of the signed Release.

Definitions:

For purposes of the Plan only, the following terms shall have the meanings described below:

“Base Salary” means the greater of your annual base salary, as determined under Company policy, as in effect on (a) the date of the closing of the Corporate Transaction or (b) the date of your Covered Termination.

“Cause” means:

• Your willful and continued material failure to perform the reasonable duties and responsibilities of your position after the Company has provided you with a written demand for performance that describes the basis for the Company’s belief that you have not substantially performed your duties and you have not corrected the failure within thirty (30) days of the written demand;

• Any act of personal dishonesty taken by you in connection with your responsibilities as an executive of the Company and intended to result in your substantial personal enrichment;

• Your conviction of, or plea of nolo contendere to, a felony that the Board of Directors of the Company reasonably believes has had or will have a material detrimental effect on the Company’s reputation or business;

• Your breach of any fiduciary duty owed to the Company by you that has a material detrimental effect on the Company’s reputation or business; or

• You being found liable in any Securities and Exchange Commission or other civil or criminal securities law action or entering any cease and desist order with respect to such action (regardless of whether or not you admit or deny liability).

“Corporate Transaction” means a merger of the Company with Roche Holding Ltd. or an affiliate of Roche Holding Ltd. other than the Company (collectively “Roche”).

“Covered Termination” means, during the eighteen (18)-month period commencing on the date of the closing of the Corporate Transaction, either:

• The Company terminates your employment without Cause; or

• You voluntarily terminate your employment with the Company for Good Reason within three (3) months of the initial existence of the condition or event that constitutes Good Reason.

Notwithstanding the foregoing, your termination of employment must constitute a “separation from service” within the meaning of Section 409A (as defined below) in order to constitute a Covered Termination with respect to any Severance Benefit deemed

Page 2

deferred compensation subject to Section 409A. Generally, you will be considered to have experienced a separation from service if, following your termination of employment, you do not continue to provide services to the Company or any of its affiliates at more than twenty percent (20%) of the average level of service you provided to the Company over the preceding three (3) years (or, if shorter, the amount of time you have been employed by the Company).

“Good Reason” means the occurrence of one or more of the following without your written consent:

• A fifteen percent (15%) or more reduction in your total annual cash compensation opportunity (base salary and target bonus opportunity collectively) as compared to your total annual cash compensation opportunity immediately prior to the closing of the Corporate Transaction;

• A change in your principal work location resulting in a new one-way commute that is more than fifty (50) miles greater than your one-way commute prior to the change in your principal work location, regardless of whether you receive an offer of relocation benefits; or

• A material reduction in your authority, duties and/or responsibilities as compared to your authority, duties and/or responsibilities in effect immediately prior to the completion of the Corporate Transaction (for example, but not by way of limitation, this determination will include an analysis of whether you maintain at least the same level, scope and type of duties and responsibilities with respect to the management, strategy, operations and business of the combined entity resulting from such transaction, taking the Company, Roche and their respective parent corporations, subsidiaries and other affiliates, together as a whole).

“Section 409A” means Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and any guidance promulgated thereunder.

“Severance Benefits” means the Severance Benefit Pay, vesting acceleration, Company-paid Health Continuation Coverage, and transitional outplacement benefits as described below.

Form of Severance Benefit Pay:

If you are an eligible executive under the Plan, the Company will pay you, at the time specified below in the section entitled “Timing of Severance Benefit Pay,” a lump sum cash severance payment (“Severance Benefit Pay”) determined as follows:

• CEO: The sum of:

(a)	three (3) times your Base Salary; plus
(b)	the average of your actual corporate regular bonus paid for the three (3) calendar years (or for the number of calendar years you have been employed if less than three (3) years) prior to the year in which your

Page 3

Covered Termination occurs expressed as a percentage of your average base salary for the same period multiplied by the value determined in (a).

• Other Executive Committee Members (including the President): The sum of:

(a)	two (2) times your annual Base Salary; plus
(b)	the average of your actual corporate regular bonus paid for the three (3) calendar years (or for the number of calendar years you have been employed if less than three (3) years) prior to the year in which your Covered Termination occurs expressed as a percentage of your average base salary for the same period multiplied by the value determined in (a).

• The EVPRDD and Senior Vice Presidents: The number of weeks of Severance Benefit Pay provided to you will be based on your length of service with the Company and your job level classification (as set by the Company) as of the date of the closing of the Corporate Transaction or the date of your Covered Termination, whichever results in the highest number of weeks of Severance Benefit Pay, as determined by the chart below. Specifically, the amount of your Severance Benefit Pay will be equal to (a) the number of weeks as determined under the chart below multiplied by (b) your Rate of Pay (as defined below). Your length of service is determined by the number of years of completed continuous service with the Company beginning with your most recent hire date through the first day of your Covered Termination. If you complete a partial year of service of at least six (6) months and one (1) day, the Company will round your length of service up to the next full year of service. If you complete a partial year of service of six (6) months or less, the Company will round your length of service down to the last full year of service.

	Weeks of Base Pay
Job Level
EVPRDD		78	80	82	84	86	88	90	92	94	96	98	100	102	104
SVP		78	80	82	84	86	88	90	92	94	96	98	100	102	104
		1	2	3	4	5	6	7	8	9	10	11	12	13	14+

Years of Service

• The Controller, the Treasurer, and Vice Presidents: Fifty-two (52) weeks multiplied by your Rate of Pay.

For purposes of this section, your Rate of Pay for one (1) week, which is used to determine Severance Benefit Pay for the EVPRDD, Senior Vice Presidents, the Controller, the Treasurer and Vice Presidents, is equal to the sum of the following:

(a)	the value of one (1) week of your Base Salary, plus
(b)	the average of your actual corporate bonus (including your regular and key contributor bonuses, as applicable) or commissions (including any incremental sales bonus) paid for the three (3) calendar years (or for the number of calendar years you have been employed if less than three (3)

Page 4

years) prior to the year in which your Covered Termination occurs expressed as a percentage of your average base salary for the same period multiplied by the value determined in (a).

If you have not yet received a corporate regular bonus because you were hired after September 30, 2007 and thus were ineligible to receive the 2007 regular corporate bonus, your Rate of Pay will be calculated as if you had received a bonus for 2007 equal to the average corporate regular bonus in 2007 for your job level classification (subject to proration for a partial year of service). If you received a prorated bonus in the prior three years (or were deemed to receive a prorated bonus under the preceding sentence) because you were hired mid-year, your Rate of Pay will be calculated using your actual paid base salary for the year in which you received the prorated bonus so that your Rate of Pay is not unfairly reduced because you received a prorated bonus.

Lump Sum Payment Reductions:

• Your Severance Benefit Pay will be reduced by legally required and authorized deductions, including, but not limited to, applicable income, employment and other tax withholding obligations, and will not be eligible for 401(k) plan elective or matching contributions or allocations under the supplemental plan.

• Payments for which you are eligible under the Plan will be reduced by any amounts you owe to the Company for any reason, except for home loans or relocation loans.

Vesting Acceleration:

If you are an eligible executive under the Plan, you will be entitled to accelerated vesting as to one hundred percent (100%) of the then unvested portion of all of your outstanding options to purchase Company common stock granted or assumed under the Company’s equity plans or assumed plans (“Company Options”) as of the date of your Covered Termination, including, without limitation, outstanding Company Options, outstanding awards to acquire Roche equity securities following an assumption or substitution of the Company Options by Roche, or any other rights substituted by Roche for Company Options, in connection with the Corporate Transaction.

Company-paid Health Continuation Coverage:

If you are an eligible executive under the Plan, you may be eligible for continued health insurance coverage under COBRA after your Covered Termination. For COBRA purposes, the date of the “qualifying event” for you and any eligible spouse or dependents that were covered under the Company’s health care plans immediately prior to the date of your Covered Termination will be the last day of the month in which your Covered Termination occurs (your “Loss of Coverage Date”).

You ordinarily must pay the full cost of COBRA coverage. However, if you make a valid election under COBRA to continue your health coverage, the Company will (for a limited time) pay the cost of such coverage for you and any eligible spouse or dependents that were covered under the Company’s health care plans immediately prior to the date of your Covered Termination as follows (“Company-paid Health Continuation Coverage”):

• CEO: You will receive Company-paid Health Continuation Coverage for a period of three (3) years from your Loss of Coverage Date.

• Other Executive Committee Members (including the President): You will receive Company-paid Health Continuation Coverage for a period of two (2) years from your Loss of Coverage Date.

• The EVPRDD and Senior Vice Presidents: You will receive Company-paid Health Continuation Coverage for the same number of weeks as your Severance Benefit Pay from your Loss of Coverage Date. For example, if you qualify for the equivalent of

Page 5

	seventy-eight (78) weeks of Severance Benefit Pay, you will also receive Company-paid Health Continuation Coverage for seventy-eight (78) weeks.
•	The Controller, the Treasurer, and Vice Presidents: You will receive Company-paid Health Continuation Coverage for fifty-two (52) weeks from your Loss of Coverage Date.

The maximum coverage period to which you are entitled under COBRA will run concurrently with your period of Company-paid Health Continuation Coverage. If the period of your Company-paid Health Continuation Coverage is less than the maximum coverage period to which you are entitled under COBRA, you may continue your health coverage after the period of your Company-paid Health Continuation Coverage for the remainder of the COBRA period at your own cost. For example, if the maximum coverage period to which you are entitled under COBRA is eighteen (18) months and you are entitled to fifty-two (52) weeks of Company-paid Health Continuation Coverage, you may continue your health coverage after the fifty-two (52) weeks of Company-paid Health Continuation Coverage for the remaining approximately six (6) months of your COBRA period at your own cost.

For the sake of clarity, any period of Company-paid Health Continuation Coverage to which you are entitled that is in excess of your maximum COBRA coverage period will be considered COBRA coverage for purposes of the Plan, and you will be entitled to Company-paid Health Continuation Coverage for the entire period set forth above, subject to the following sentence. Company-paid Health Continuation Coverage will stop for you if you become eligible to obtain comparable health care benefits from another employer.

Transitional Outplacement Benefits:

If you are an eligible executive under the Plan, you will be provided transitional outplacement benefits for as long as you are actively seeking employment during the period of time beginning on the date of your Covered Termination and ending one hundred and eighty (180) calendar days thereafter, through a firm designated by the Company; provided that the total cost of your transitional outplacement benefits may not exceed the following dollar amounts:

• CEO and other Executive Committee Members (including the President): $8,000.

• The EVPRDD, Senior Vice Presidents, the Controller, the Treasurer, and Vice Presidents: $6,000.

2008 Bonuses:

Page 6

If the closing of a Corporate Transaction occurs while you remain an employee of the Company, you will be paid your earned and accrued bonus, if any, under the 2008 Bonus Plan at the time the 2008 bonus otherwise would have been paid, regardless of whether you remain employed with the Company through such date unless, following the closing of a Corporate Transaction, your employment is voluntarily or involuntarily terminated under circumstances that would not otherwise constitute a Covered Termination. If the closing of a Corporate Transaction occurs prior to the end of the Company’s 2008 fiscal year, the applicable corporate performance goals that would have been measured as of the end of such year will be deemed achieved (the “Annual Corporate Performance Goals”). The amount of the 2008 Bonus Plan pool will be determined based on (i) the deemed achievement of the Annual Corporate Performance Goals and (ii) the actual year-to-date achievement of any applicable performance goals other than the Annual Corporate Performance Goals. If the 2008 Bonus Plan pool equals or exceeds the predetermined 2008 Bonus Plan maximum payout, your 2008 bonus will equal the percentage of base salary used for the 2007 Bonus Plan recommended payout for your 2008 job level classification. If the 2008 Bonus Plan pool is less than the predetermined 2008 Bonus Plan maximum payout, your 2008 bonus will equal the percentage of base salary used for the 2007 Bonus Plan recommended payout for your 2008 job level classification reduced proportionately as appropriate. Once the percentage of base salary is determined in accordance with the foregoing, such percentage will be applied to the greater of your annual base salary as in effect on December 31, 2008 or the date of the Corporate Transaction. For example: In 2008, an employee’s job level classification is D1. In 2007, the percentage of base salary used for the 2007 Bonus Plan recommended payout for a D1 was 36%. If the employee’s salary is $150,000 on the date of the Corporate Transaction (and his/her salary is not increased for the remainder of 2008), the employee will receive a 2008 bonus payout of $54,000 if the 2008 Bonus Plan pool equals or exceeds the predetermined 2008 Bonus Plan maximum payout.

Exclusive Benefit:

The severance provisions of the Plan, together with any benefits payable to you under the Genentech, Inc. Executive Retention Plan (the “Retention Plan”) upon a Covered Termination, are intended to be and are exclusive and in lieu of any other rights or remedies to which you may otherwise be entitled, either at law, tort, or contract, in equity, or under the Plan, in the event of any termination of your employment. You will be entitled to no benefits, compensation or other payments or rights upon a termination of employment that constitutes a Covered Termination other than those benefits expressly set forth herein and in the Retention Plan and those benefits required to be provided by law, subject to the following sentence. Notwithstanding the foregoing, if you are entitled to any benefits other than the benefits under the Plan by operation of applicable law, your benefits under the Plan shall be reduced by the value of the benefits you receive by operation of applicable law, as determined by the Company in its discretion.

Agreement and Release:

To qualify for the Severance Benefits described above, you must execute and not revoke during any applicable revocation period the Release, in the form attached to the Plan as Exhibit A with any additional revisions as required by law. The Release is an agreement, signed by you and the Company, in which you agree to give up any and all claims, actions or lawsuits against the Company that relate to your employment with the Company. You will be given a copy of this Release no later than the date of your Covered Termination. The Release will include specific information regarding the amount of time you will have to consider the terms of the Release and return the signed agreement to the Company. In no event will the period to return the Release be longer than sixty (60) days following your Covered Termination, inclusive of any revocation period set forth in the Release.

Timing of Severance Benefit Pay:

If your Covered Termination occurs on or before October 15 of a calendar year, you will receive your Severance Benefit Pay on or before December 31 of that calendar year, except as otherwise provided in the section below entitled “Delay in Payment Timing in Certain Limited Circumstances”. If your Covered Termination occurs after October 15, you will receive your Severance Benefit Pay on the later of (a) the second payroll date in the calendar year next following the calendar year of your Covered Termination or (b)

Page 7

the first payroll date following the date your Release becomes effective, except as otherwise provided in the section below entitled “Delay in Payment Timing in Certain Limited Circumstances”.

Delay in Payment Timing in Certain Limited Circumstances:

In certain circumstances, the Company may need to delay the payment of your Severance Benefits under the Plan. If the Company determines that you are a “specified employee” within the meaning of Section 409A at the time of your Covered Termination, then to the extent delayed commencement of any portion of the benefits to which you are entitled pursuant to the Plan, when considered together with any other payments or benefits that are considered deferred compensation under Section 409A (together, the “Deferred Compensation Separation Benefits”), is required to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such benefits will be delayed until the first payroll date that occurs on or after the date that is six (6) months and one (1) day after the date of your Covered Termination. All subsequent Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. You generally will be a specified employee only if (among other things) you own at least one percent (1%) of the Company’s stock or are considered an officer of the Company. The Company will inform you if it determines that you are a specified employee at the time of your Covered Termination. If you die following your Covered Termination but prior to the six (6) month anniversary of your Covered Termination, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of your death.

To the extent that any reimbursements payable pursuant to the Plan are subject to Section 409A, any such reimbursements payable to you pursuant to the Plan shall be paid to you no later than December 31 of the year following the year in which the expense was incurred, the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year, and your right to reimbursement under the Plan will not be subject to liquidation or exchange for another benefit.

The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the Plan’s benefits will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company reserves the right to amend the Plan and to take such reasonable actions which are necessary, appropriate, or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to you under Section 409A, provided that such amendment or action may not materially reduce the benefits provided or to be provided to you under the Plan. In no event will the Company reimburse you for any taxes that may be imposed on you as a result of Section 409A.

Filing a Claim:

Normally, Severance Benefits automatically will be provided to all eligible executives who qualify. However, if you have not received these benefits and you believe you are entitled to them, or if you believe you are entitled to a larger benefit than you are

Page 8

receiving, you may file a claim with the Plan Administrator within ninety (90) days of any of the following dates, whichever is first:

• The date you learned the amount of your Severance Benefits under the Plan; or

• The date you learned there will be no Severance Benefits for you under the Plan.

Your claim must be in writing, signed by you or your legal representative and briefly explain the basis for the claim. The claim should be delivered to the Plan in care of the Plan Administrator as follows:

Genentech, Inc., Executive Severance Plan
c/o, Plan Administrator
Genentech, Inc.
1 DNA Way, MS 91
South San Francisco, CA 94080

The Plan Administrator has delegated the claims review responsibility to the Company’s Director of Employee Benefits. The Director of Employee Benefits will work with your Human Resources Manager to research your claim and will approve or deny the claim in a written response to you within thirty (30) days of their receiving your claim (if an additional thirty (30) days are required to reach a decision, you will be notified in writing within the initial thirty (30) day period). If the claim is wholly or partially denied, you will receive a written notice specifying (a) the reasons for the denial, (b) the specific Plan provisions on which the decision is based, and (c) any additional information needed from you in connection with your claim and why such information is needed.

Appeal Process:

The Plan Administrator has delegated the responsibility to review appeals to the Company’s General Counsel. If all or part of your claim is denied, you or your legal representative may appeal for a review of your claim by notifying the General Counsel in writing within sixty (60) days of receiving the written notice that your claim was denied. You may receive pertinent Plan documents by request to the Plan Administrator. Your request for review may (but is not required to) include issues and comments you want considered in the review. The appeal should be delivered to the General Counsel as follows:

Genentech, Inc., Executive Severance Plan (Appeal)
c/o, General Counsel
Genentech, Inc.
1 DNA Way, MS 49
South San Francisco, CA 94080

Within sixty (60) days of receiving your appeal, you will receive a written response from the General Counsel setting forth (a) a decision; or (b) a notice describing special circumstances requiring additional time for review (but not more than one hundred and

Page 9

twenty (120) days from the General Counsel’s receipt of your appeal). A decision will be in writing and will specify the Plan provisions on which it is based. If you do not receive a decision within the specified time, you should assume your appeal was denied.

Attorneys’ Fees:

In the event that either party (you or the Company) brings an action to enforce or effect its rights under the Plan and you prevail on at least one material issue in the action, the Company will reimburse you for your costs and expenses incurred in connection with the action, including the costs of mediation, arbitration, litigation, court fees, and reasonable attorneys’ fees.

The Company’s Successors:

Any successor to the Company of all or substantially all of the Company’s business and/or assets (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise), will assume the obligations under the Plan and agree expressly to perform the obligations under the Plan in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under the Plan, the term “Company” will include any successor to the Company’s business and/or assets which become bound by the terms of the Plan by operation of law, or otherwise.

Name, Type and Number of Plan:

The name of the Plan is the “Genentech, Inc. Executive Severance Plan.” The Plan is a severance plan. The Internal Revenue Service and the Department of Labor identify the Plan by its name and by the Plan identification number 519.

Plan Sponsor:

The name of the employer sponsoring the Plan is:

Genentech, Inc.,
EIN: 94-2347624
1 DNA Way
South San Francisco, CA 94080

Plan Administrator:

The Plan Administrator is the Special Committee of the Board of Directors of the Company, duly constituted by resolution of the Board of Directors adopted by unanimous written consent on July 24, 2008 (the “Special Committee”), or in the event the Special Committee is dissolved by the Board of Directors, then another duly constituted committee of members of the Board of Directors, or officers of the Company as delegated by the Board of Directors. The Plan Administrator will have the power to construe the terms of the Plan and perform such acts as it deems necessary or appropriate to effect the purpose of the Plan.

The Plan Administrator will not be liable for any action or determination made by the Plan Administrator with respect to the Plan or any distribution paid under the Plan. All expenses and liabilities that the Plan Administrator incurs in connection with the

Page 10

administration of the Plan will be borne by the Company. The Plan Administrator will not be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or any distribution paid hereunder, and the Plan Administrator will be fully indemnified and held harmless by the Company in respect of any such action, determination or interpretation.

Communications to Genentech, Inc., in its capacity as Plan Administrator of the Plan, should be addressed to:

Genentech, Inc., Executive Severance Plan
c/o, Plan Administrator
Genentech, Inc.,
1 DNA Way, MS 91
South San Francisco, CA 94080

Plan Year:

Financial records for the Plan are kept on a “Plan Year” basis. The Plan Year is the twelve (12) month period beginning each January 1 and ending on the following December 31.

ERISA Rights:

As a participant in the Plan, you are entitled to certain rights and protections under the Employment Retirement Income Security Act of 1974 (ERISA). ERISA provides that you, and all Plan participants, shall be entitled to:

• Examine, without charge, at your employer’s office, all Plan documents and copies of all documents filed by the Plan with the U.S. Department of Labor.

• Obtain copies of all pertinent Plan information upon written request to your employer. Your employer may make a reasonable charge for the copies.

In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the Plan. The people who operate the Plan, called “fiduciaries” of the Plan, have a duty to do so prudently and in the interest of you and other Plan participants and beneficiaries. No one, including your employer, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a benefit or exercising your rights under ERISA. If your claim for a benefit is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request materials from the Plan and do not receive them within thirty (30) days, you may file suit in a federal court. In such a case, the court may require your employer to provide the materials and pay you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of your employer. If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in federal court. If it should happen that Plan

Page 11

fiduciaries misuse the Plan’s money, or if you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court. The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous. If you have any questions about your Plan, you should contact your employer.

If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining Plan documents, you should contact the nearest Area Office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory, or you may contact:

Division of Technical Assistance and Inquiries
Employee Benefits Security Administration
U.S. Department of Labor
200 Constitution Avenue, N.W.
Washington DC 20210

You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.

Service of Legal Process:

The Plan Administrator is designated as agent to service of legal process against the Plan.

Amendment and Termination of the Plan:

Although the Company currently expects to continue the Plan, the Company reserves the right to amend or terminate the Plan at any time. After a Corporate Transaction, without the executive’s written consent, the Company may not amend or terminate the Plan in any way, nor take any other action, that (a) prevents an executive from becoming eligible for Severance Benefits under the Plan, (b) reduces the amount of Severance Benefits payable, or potentially payable, to an executive under the Plan, or (c) reduces the amount of the 2008 bonus payable under the 2008 Bonus Plan, if any. Any Plan amendment or termination will be made in writing and approved by the Plan Administrator.

Nature of Benefits:

When benefits are due, they are paid from the general assets of the Company. These assets are subject to the general creditors of the Company. You will have no rights under the Plan other than as unsecured general creditors of the Company. No provision of the Plan will require the Company, for the purpose of satisfying any obligations under the Plan, to purchase assets or place any assets in a trust or other entity to which contributions are made or otherwise to segregate any assets, nor will the Company maintain separate bank accounts, books, records or other evidence of the existence of a segregated or separately maintained or administered fund for such purposes. Nothing contained in the Plan will create or be construed to create a trust of any kind. The

Page 12

Company is not required to establish a trust to fund the Plan, but it may choose to do so at its discretion. No property which may be acquired or invested by the Company in connection with the Plan will be deemed a security for the obligations to you under the Plan, but will be, and continue for all purposes to be, part of the general funds of the Company.

Nonassignability:

To the maximum extent permitted by law, your rights or benefits under the Plan will not be subject to anticipation, alienation, sale, assignment, pledge, encumbrance or charge, and any attempt to anticipate, alienate, sell, assign, pledge, encumber or charge the same will be void. No right or benefit hereunder will in any manner be liable for or subject to the debts, contracts, liabilities or torts of the person entitled to such benefit.

Rights Under the Plan:

This section will survive the closing of the Corporate Transaction. The Plan is intended to benefit, and may be enforced by, the eligible executives and their respective heirs, representatives, successors and assigns, and will be binding on all successors and assigns of the Company and Roche.

No Guarantee of Future Service:

Notwithstanding anything in the Plan to the contrary, your eligibility to participate in the Plan will not provide you with any guarantee or promise of continued service with the Company, and the Company retains the right to terminate your employment at any time, with or without Cause, for any reason or no reason. However, as described in the Plan, you may be entitled to benefits under the Plan depending upon the circumstances of your termination of employment.

Questions:

If you have any questions about the Plan, first contact the Human Resources Department. If you still have questions, you may contact the Legal Department.

o O o

Page 13

EXHIBIT A

Forms of Agreement and Release

AGREEMENT AND RELEASE
[FOR USE WITH EXECUTIVES 40 AND OVER]

     This Agreement and Release (“Agreement”) is made by and between [CLICK AND TYPE NAME] (“Employee”) and Genentech, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).

     WHEREAS, in connection with the Employee’s termination of employment effective                     , 200___, the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that the Employee may have against the Company and any of the Releasees as defined below, including, but not limited to, any and all claims arising out of or in any way related to Employee’s employment with or separation from the Company.

     NOW, THEREFORE, in consideration of the mutual promises made herein, the Company and Employee hereby agree as follows:

     1. Consideration, Payment of Salary and Receipt of All Benefits. The Company agrees to provide Employee with the Severance Benefits set forth in the Genentech, Inc. Executive Severance Plan in accordance with the terms and conditions of such plan. Employee acknowledges and represents that the Company has otherwise paid or provided all salary, wages, bonuses, accrued vacation/paid time off, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses, commissions, stock, stock options, vesting, and any and all other benefits and compensation due to Employee.

     2. Release of Claims. Employee agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to Employee by the Company and its current and former officers, directors, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries, and predecessor and successor corporations and assigns (collectively, the “Releasees”). Employee, on his/her own behalf and on behalf of his/her respective heirs, family members, executors, agents, and assigns, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Employee may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including the Effective Date of this Agreement (as defined in Section 8 below), including, without limitation:

          a. any and all claims relating to or arising from Employee’s employment relationship with the Company and the termination of that relationship;

          b. any and all claims relating to, or arising from, Employee’s right to purchase, or actual purchase of shares of stock of the Company, including, without

Page 1

limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law;

          c. any and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits;

          d. any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the Fair Labor Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act; the Family and Medical Leave Act; the Sarbanes-Oxley Act of 2002; the California Family Rights Act; the California Labor Code; the California Workers’ Compensation Act; and the California Fair Employment and Housing Act;

          e. any and all claims for violation of the federal or any state constitution;

          f. any and all claims arising out of any other laws and regulations relating to employment or employment discrimination;

          g. any claim for any loss, cost, damage, or expense arising out of any dispute over the nonwithholding or other tax treatment of any of the proceeds received by Employee as a result of this Agreement; and

          h. any and all claims for attorneys’ fees and costs.

     Employee agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released. This release does not release claims that cannot be released as a matter of law, including, but not limited to, Employee’s right to file a charge with or participate in a charge by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against the Company (with the understanding that Employee’s release of claims herein bars Employee from recovering such monetary relief from the Company), claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain

Page 2

of the Company’s group benefit plans pursuant to the terms and conditions of COBRA, claims to any benefit entitlements vested as the date of separation of Employee’s employment, pursuant to written terms of any employee benefit plan of the Company or its affiliates and Employee’s right under applicable law and the Company’s D&O policy to seek indemnity for acts committed, or omissions, within the course and scope of the Employee’s employment duties.

     3. Acknowledgment of Waiver of Claims under ADEA. Employee understands and acknowledges that he/she is waiving and releasing any rights he/she may have under the Age Discrimination in Employment Act of 1967 (“ADEA”), and that this waiver and release is knowing and voluntary. Employee understands and agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Effective Date of this Agreement. Employee understands and acknowledges that the consideration given for this waiver and release is in addition to anything of value to which Employee was already entitled. Employee further understands and acknowledges that he/she has been advised by this writing that: (a) he/she should consult with an attorney prior to executing this Agreement; (b) he/she has forty-five (45) days within which to consider this Agreement; (c) he/she has received a Decisional Unit Information Letter from the Company advising Employee of the class, unit, or group of individuals covered by the reduction in force, the eligibility factors for the reduction in force, and the job titles and ages of all individuals who were and were not selected; (d) he/she has seven (7) days following his/her execution of this Agreement to revoke this Agreement; (e) this Agreement shall not be effective until after the revocation period has expired; and (f) nothing in this Agreement prevents or precludes Employee from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Employee signs this Agreement and returns it to the Company in less than the forty-five (45) day period identified above, Employee hereby acknowledges that he/she has freely and voluntarily chosen to waive the time period allotted for considering this Agreement.

     4. California Civil Code Section 1542. Employee acknowledges that he/she has been advised to consult with legal counsel and is familiar with the provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

     Employee, being aware of said code section, agrees to expressly waive any rights he/she may have thereunder, as well as under any other statute or common law principles of similar effect.

Page 3

     5. Severability. In the event that any provision or any portion of any provision hereof or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision or portion of provision.

     6. No Oral Modification. This Agreement may only be amended in a writing signed by Employee and a duly authorized officer of the Company.

     7. Governing Law. This Agreement shall be governed by the laws of the State of California, without regard for choice-of-law provisions. Employee consents to personal and exclusive jurisdiction and venue in the State of California.

     8. Effective Date. Each Party has seven (7) days after that Party signs this Agreement to revoke it. This Agreement will become effective on the eighth (8th) day after Employee signed this Agreement, so long as it has been signed by the Parties and has not been revoked by either Party before that date (the “Effective Date”).

     9. Voluntary Execution of Agreement. Employee understands and agrees that he/she executed this Agreement voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of his/her claims against the Company and any of the other Releasees. Employee acknowledges that: (a) he/she has read this Agreement; (b) he/she has not relied upon any representations or statements made by the Company that are not specifically set forth in this Agreement; (c) he/she has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of his/her own choice or has elected not to retain legal counsel; (d) he/she understands the terms and consequences of this Agreement and of the releases it contains; and (e) he/she is fully aware of the legal and binding effect of this Agreement.

o O o

Page 4

     IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set forth below.

	[CLICK & TYPE NAME], an individual
Dated:
	[Click and Type Employee Name]
	GENENTECH, INC.
Dated:	By
		[Click and Type Officer Name]
		[Click and Type Title]

Page 5

AGREEMENT AND RELEASE
[FOR USE WITH EXECUTIVES UNDER 40]

     This Agreement and Release (“Agreement”) is made by and between [CLICK AND TYPE NAME] (“Employee”) and Genentech, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”), effective on the date it has been signed by both Parties (the “Effective Date”).

     WHEREAS, in connection with the Employee’s termination of employment effective                     , 200___, the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that the Employee may have against the Company and any of the Releasees as defined below, including, but not limited to, any and all claims arising out of or in any way related to Employee’s employment with or separation from the Company.

     NOW, THEREFORE, in consideration of the mutual promises made herein, the Company and Employee hereby agree as follows:

     1. Consideration, Payment of Salary and Receipt of All Benefits. The Company agrees to provide Employee with the Severance Benefits set forth in the Genentech, Inc. Executive Severance Plan in accordance with the terms and conditions of such plan. Employee acknowledges and represents that the Company has otherwise paid or provided all salary, wages, bonuses, accrued vacation/paid time off, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses, commissions, stock, stock options, vesting, and any and all other benefits and compensation due to Employee.

     2. Release of Claims. Employee agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed to Employee by the Company and its current and former officers, directors, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries, and predecessor and successor corporations and assigns (collectively, the “Releasees”). Employee, on his/her own behalf and on behalf of his/her respective heirs, family members, executors, agents, and assigns, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Employee may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including the Effective Date of this Agreement, including, without limitation:

          a. any and all claims relating to or arising from Employee’s employment relationship with the Company and the termination of that relationship;

          b. any and all claims relating to, or arising from, Employee’s right to purchase, or actual purchase of shares of stock of the Company, including, without

Page 1

limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law;

          c. any and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits;

          d. any and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the Fair Labor Standards Act; the Fair Credit Reporting Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act; the Family and Medical Leave Act; the Sarbanes-Oxley Act of 2002; the California Family Rights Act; the California Labor Code; the California Workers’ Compensation Act; and the California Fair Employment and Housing Act;

          e. any and all claims for violation of the federal or any state constitution;

          f. any and all claims arising out of any other laws and regulations relating to employment or employment discrimination;

          g. any claim for any loss, cost, damage, or expense arising out of any dispute over the nonwithholding or other tax treatment of any of the proceeds received by Employee as a result of this Agreement; and

          h. any and all claims for attorneys’ fees and costs.

     Employee agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released. This release does not release claims that cannot be released as a matter of law, including, but not limited to, Employee’s right to file a charge with or participate in a charge by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against the Company (with the understanding that Employee’s release of claims herein bars Employee from recovering such monetary relief from the Company) , claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company’s group benefit plans pursuant to the terms and conditions of COBRA and claims to any benefit entitlements vested as the date of

Page 2

separation of Employee’s employment, pursuant to written terms of any employee benefit plan of the Company or its affiliates.

     3. California Civil Code Section 1542. Employee acknowledges that he/she has been advised to consult with legal counsel and is familiar with the provisions of California Civil Code Section 1542, a statute that otherwise prohibits the release of unknown claims, which provides:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

     Employee, being aware of said code section, agrees to expressly waive any rights he/she may have thereunder, as well as under any other statute or common law principles of similar effect.

     4. Severability. In the event that any provision or any portion of any provision hereof or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision or portion of provision.

     5. No Oral Modification. This Agreement may only be amended in a writing signed by Employee and a duly authorized officer of the Company.

     6. Governing Law. This Agreement shall be governed by the laws of the State of California, without regard for choice-of-law provisions. Employee consents to personal and exclusive jurisdiction and venue in the State of California.

     7. Voluntary Execution of Agreement. Employee understands and agrees that he/she executed this Agreement voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of his/her claims against the Company and any of the other Releasees. Employee acknowledges that: (a) he/she has read this Agreement; (b) he/she has not relied upon any representations or statements made by the Company that are not specifically set forth in this Agreement; (c) he/she has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of his/her own choice or has elected not to retain legal counsel; (d) he/she understands the terms and consequences of this Agreement and of the releases it contains; and (e) he/she is fully aware of the legal and binding effect of this Agreement.

o O o

Page 3

     IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set forth below.

	[CLICK & TYPE NAME], an individual
Dated:
	[Click and Type Employee Name]
	GENENTECH, INC.
Dated:	By
	[Click and Type Officer Name]
	[Click and Type Title]

Page 4